Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
Coforge rallies 6% after Q2 net profit rockets 86% YoY. Should you buy, sell or hold ?
27/10/2025
6 IPOs to open subscription this week. GMPs suggest investors could bag returns up to 17%
27/10/2025
Can Nifty break records this week ? Here’s what the charts say
27/10/2025
Asian stocks rally as trade tensions ease, gold drops
27/10/2025
Adani Group's long-term bonds continue to interest institutions
27/10/2025
FPIs turn bullish on India as short covering drives market higher
27/10/2025
